[1]王根强,龙登毅,贝宁,等.尤瑞克林联合阿司匹林治疗急性脑梗死效果及安全性[J].青岛大学学报(医学版),2018,54(04):389-392.[doi:10.11712/jms201804003]
 WANG Genqiang,LONG Dengyi,BEI Ning,et al.CLINICAL EFFICACY AND SAFETY OF URINARY KALLIDINOGENASE COMBINED WITH ASPIRIN IN TREATMENT OF ACUTE CEREBRAL INFARCTION[J].JOURNAL OF QINGDAO UNIVERSITY (MEDICAL SCIENCES),2018,54(04):389-392.[doi:10.11712/jms201804003]
点击复制

尤瑞克林联合阿司匹林治疗急性脑梗死效果及安全性()
分享到:

《青岛大学学报(医学版)》[ISSN:2096-5532/CN:37-1217/R]

卷:
第54卷
期数:
2018年04期
页码:
389-392
栏目:
出版日期:
2018-07-05

文章信息/Info

Title:
CLINICAL EFFICACY AND SAFETY OF URINARY KALLIDINOGENASE COMBINED WITH ASPIRIN IN TREATMENT OF ACUTE CEREBRAL INFARCTION
文章编号:
2096-5532(2018)04-0389-04
作者:
王根强龙登毅贝宁贝筝焦宏伟
(海南省干部疗养院三科,海南 海口 571100)
Author(s):
WANG Genqiang LONG Dengyi BEI Ning BEI Zheng JIAO Hongwei
(The Third Department, Hainan Province Cadre Sanatorium, Haikou 571100, China)
关键词:
脑梗死阿司匹林激肽释放酶类治疗结果安全
Keywords:
brain infarction aspirin kallidinogenase treatment outcome safety
分类号:
R743.33
DOI:
10.11712/jms201804003
文献标志码:
A
摘要:
目的 探讨尤瑞克林联合阿司匹林治疗急性脑梗死的临床效果及安全性。
方法 将2014年2月—2017年2月在我院住院治疗的172例急性脑梗死病人随机分为2组,每组86例病人。对照组予以阿司匹林口服,研究组在阿司匹林口服治疗的基础上,静脉给予尤瑞克林。治疗2周后,比较两组病人的血液流变学指标、临床疗效及同型半胱氨酸(Hcy)、血管内皮生长因子(VEGF)、超敏C反应蛋白(hs-CRP)、胱抑素C(Cys-C)、白细胞介素6(IL-6)等血清学指标和药物不良反应。
结果 两组病人治疗后的全血黏度、血浆黏度及血小板聚集率均显著低于治疗前(t=4.027~11.452,P<0.05),且研究组病人治疗后的全血黏度、血浆黏度及血小板聚集率均低于对照组治疗后(t=5.793~10.862,P<0.05)。研究组病人的治疗有效率为93.1%,明显高于对照组的69.8%(χ2=5.454,P<0.05)。两组病人治疗后的Hcy、hs-CRP、Cys-C、IL-6水平及研究组治疗后的VEGF水平均明显低于治疗前(t=4.014~26.994,P<0.05),且研究组治疗后的Hcy、hs-CRP、Cys-C、IL-6水平显著低于对照组治疗后(t=3.872~26.552,P<0.05)。治疗期间,研究组和对照组的药物不良反应发生率分别为15.1%和12.8%,差异无统计学意义(P>0.05)。
结论 尤瑞克林联合阿司匹林治疗急性脑梗死具有良好的临床效果和可靠的安全性。
Abstract:
Objective To analyze the clinical efficacy and safety of urinary kallidinogenase combined with aspirin in the treatment of acute cerebral infarction.
Methods A total of 172 patients with acute cerebral infarction hospitalized in our hospital from February 2014 to February 2017 were randomly divided into control group and study group, with 86 patients in each group. The control group was given oral aspirin, and the study group was given intravenous urinary kallidinogenase in addition to oral aspirin treatment. After two weeks of treatment, the two groups were compared in terms of hemorheological indices, clinical outcome, homocysteine (Hcy), vascular endothelial growth factor (VEGF), hypersensitive C-reactive protein (hs-CRP), cystatin C (Cys-C), interleukin-6 (IL-6), and the incidence of adverse drug reactions.
Results Both groups showed significant reductions in whole blood viscosity, plasma viscosity, and platelet aggregation rate after treatment (t=4.027-11.452, P<0.05), and the three indices were significantly lower in the study group than in the control group after treatment (t=5.793-10.862, P<0.05). The study group had a significantly higher response rate than the control group (93.1% vs 69.8%,χ2=5.454, P<0.05). The levels of Hcy, hs-CRP, Cys-C, and IL-6 in the two groups and the VEGF level in the study group were significantly reduced after treatment (t=4.014-26.994, P<0.05), and the levels of Hcy, hs-CRP, Cys-C, and IL-6 in the study group were significantly lower than those in the control group after treatment (t=3.872-26.552, P<0.05). During the treatment, the incidence of adverse drug reactions was not significantly different between the study group and the control group (15.1% vs 12.8%, P>0.05).
Conclusion Urinary kallidinogenase combined with aspirin has good clinical efficacy and reliable safety in the treatment of acute cerebral infarction.
更新日期/Last Update: 2018-07-08